A novel 12-hour versus 24-hour magnesium sulfate regimen in the management of eclampsia and preeclampsia in Ghana (MOPEP Study): A randomized controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Prospective registration was with Pan African Clinical Trial Registry (PACTR201811515303983): https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=4690.

Who Took Part

PubMed indexes the participants as adults, women only.

The primary outcome was occurrence of seizure after completion of the assigned magnesium sulfate regimen.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

This is an open-labeled parallel randomized controlled trial conducted in Accra, Ghana from November 2018 to November 2020.

What Was Measured

Topics PubMed links to this paper include Anticonvulsants, Eclampsia, Ghana, Magnesium Sulfate, Pre-Eclampsia and Seizures.

The authors tagged it with the keywords preeclampsia and seizure prophylaxis.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.